Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

By M. Roden, T. Zaoutis, Wendy L. Buchanan, T. Knudsen, Tatyana A Sarkisova, R. Schaufele, M. Sein, Tin Sein., C. Chiou, Jaclyn H. Chu and 2 more. Clinical Infectious Diseases, 2005

2,922 citations recorded by the source corpus.

Subfields: Infectious Diseases, Ophthalmology, Small Animals

View Paper: https://www.semanticscholar.org/paper/d3a4b01f1e39d5d2b87b9a3238c2e5ea6cde138b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis
5. Georgios Chamilos
6. M. Nucci
7. M. Malangoni
8. J. Ustin

In Small Animals

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. M. Nucci
5. D. Kontoyiannis

Citations in the corpus

• Global Epidemiology of Mucormycosis (2019, background): “Multiple sites of infection were reported in few studies: Roden et al. 2005 [3], Ruping et al. 2010 [75], Kennedy et al. 2016 [85].”
• Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium (2019, background): “11,17,66,109 It is effective, but its use is limited by its substantial toxicity, specifically in the doses and treatment durations needed for mucormycosis (table 2).”
• Pathogenesis of mucormycosis. (2012, background): “Rhizopus oryzae is the most common organism isolated from patients with mucormycosis and is responsible for 70% of all cases of mucormycosis [2–4].”
• Histopathologic Diagnosis of Fungal Infections in the 21st Century (2011, background): “Mortality due to disseminated disease is extremely high but varies depending on the associated risk factor and clinical presentation (137).”
• Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, background): “In agreement with the published literature [3, 4, 2123], we found several host factors that reflect underlying im-”
• One stop shop: backbones trees for important phytopathogenic genera: I (2014) (2014, neutral): “(Pitt and Hocking 2009), mostly in immunocompromised patients (Roden et al. 2005; Pitt and Hocking 2009; Chakrabarti et al. 2010; Skiada et al. 2011).”
• Epidemiology and clinical manifestations of mucormycosis. (2012, background): “In such cases, diagnosis is delayed, and the mortality rate is as high as 85% [27].”
• Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. (2011, background): “[4], the respective percentage was only 5%.”
• Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (2006, background): “These data compare favorably with data for patients who have received amphotericin B products, among whom the survival rate has been reported to be 61% for recipients of amphotericin B deoxycholate and 69% for recipients of lipid formulations [2].”
• Primary small bowel mesentery de-differentiated liposarcoma causing torsion with no recurrence for 5 years (2018, neutral): “Gastrointestinal manifestations of mucormycosis account for only 7% of all cases,([3]) with the stomach being the most frequently affected organ.”
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. (2014, background): “In particular, the clinical picture may be different depending on the species [3,5,57].”
• Epidemiology of Invasive Mycoses in North America (2010, background): “…Scedosporium, Scopulariopsis, Paecilomyces, and Trichoderma species, and a wide variety of dematiaceous fungi (Table 2) (Castelle et al. 2008; Cortez et al. 2008; Nucci et al. 2007; Pfaller et al. 2007d; Pfaller et al. 2009a; Procop et al. 2004; Richardson et al. 2008; Roden et al. 2005; Sutton.”
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, methodology): “The ECIL-3 recommendations for the treatment of mucormycosis were mostly based on retrospective studies, registry data and small prospective non-controlled studies.(3,68-77) Few new data are available for the treatment of mucormycosis since the ECIL 4 and, therefore, the current recommendations are ”
• Necrotizing soft-tissue infections (2011, background): “Conditions predisposing to these infections include diabetes mellitus, hematologic malignancies, organ transplantation, steroid use, acquired immunodeficiency syndrome, treatment with desferoxamine, and iron overload (65, 67, 68).”